Open Access

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

  • Klára Gadó1Email author,
  • András Matolcsy2,
  • Judit Csomor2,
  • Dóra Kicsi3,
  • Csaba Bödör2 and
  • Gyula Domján1
Experimental Hematology & Oncology20121:17

DOI: 10.1186/2162-3619-1-17

Received: 24 March 2012

Accepted: 27 April 2012

Published: 11 July 2012

Abstract

Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation of dasatinib.

Keywords

Chronic myeloid leukemia Dasatinib Imatinib Tyrosine kinase inhibitor Drug intolerance

Summary

Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation of dasatinib.

The introduction of tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy [1]. Approximately 30% of patients receiving imatinib as first-line therapy will discontinue treatment by 5 years because of imatinib resistance or drug toxicity [2].

Second generation TKIs (dasatinib, nilotinib) are indicated for those patients who are refractory or intolerant to imatinib [3, 4]. However, after stopping TKI administration, relapse comes about inevi, so the present guidelines recommend continuous drug dosing [5]. While there is an ongoing prospective study with imatinib (Stop Imatinib study) [6], no available data arising from controlled studies exists with dasatinib concerning the optimal duration of therapy. Consequently, discontinuation of dasatinib is not recommended outside of clinical trials but remains an active area of research [7].

Our patient, a 84 year old lady with a chronic phase CML was intolerant to imatinib. She was given dasatinib as second line treatment. Though a reduced dose of 50 mg daily was applied, a complete molecular remission developed within two months. After four months she suspended taking the drug because of intolerance (pleural effusion, congestive heart failure, Adams-Stokes syndrome had been developed), but complete molecular remission was lasting till one year after stopping dasatinib. The patient did not receive any kind of anti-CML therapy during this year. After one year without any TKI, the expression level of BCR/ABL major fusion gene has increased gradually, but even now, 27 months after stopping dasatinib treatment, the patient is still in minor molecular remission (Figure1).
https://static-content.springer.com/image/art%3A10.1186%2F2162-3619-1-17/MediaObjects/40164_2012_Article_21_Fig1_HTML.jpg
Figure 1

Expression level of BCR-ABL major fusion gene at various time during therapy measured by real-time quantitative PCR using ABL gene amplification as a control.

Because of her several kind of comorbidities, her good quality of life, the actual hematological remission and also her reluctance to take any kind of TKIs, our therapeutical strategy is only watch and wait.

This is the first report about maintaining complete molecular remission after one year of suspending dasatinib treatment.

Abbreviations

CML: 

Chronic myeloid leukemia

TKI: 

Tyrosine kinase inhibitor.

Declarations

Authors’ Affiliations

(1)
1st Department of Internal Medicine, Semmelweis University
(2)
1st Department of Pathology and Experimental Cancer Research, Semmelweis University
(3)
Department of Internal Medicine, St Rokus Hospital

References

  1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003,348(11):994–1004. 10.1056/NEJMoa022457PubMedView Article
  2. Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M: Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors–the first molecular targeted treatment. J Med Life. 2010,3(2):162–6.PubMed CentralPubMed
  3. Aguilera DG, Tsimberidou AM: Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009,5(2):281–9.PubMed CentralPubMed
  4. Stein B, Smith BD: Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010,32(5):804–20. 10.1016/j.clinthera.2010.05.003PubMed CentralPubMedView Article
  5. Traer E, Deininger MW: How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010,10(Suppl 1):S20–6.PubMedView Article
  6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010,11(11):1029–35. 10.1016/S1470-2045(10)70233-3PubMedView Article
  7. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009,27(35):6041–51. 10.1200/JCO.2009.25.0779PubMedView Article

Copyright

© Gado et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement